Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
23847studies shown
Showing 14,041-14,052 of 23,847
Behavioral study icon
Active Not RecruitingNCT05384223

Evaluation of RRFT for Co-occurring SUD and PTSD Among Teens

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Aurora
PTSD, AddictionBehavioralFrom 13 Years to 75 Years
Countries
United States
Sponsor
Medical University of South Carolina
Condition
PTSD, Addiction
Drug study icon
CompletedNCT03247556

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD

This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication SPN-812 in practice and what may need to be adjusted.

Multiple locations, including Long Beach
ADHDDrugFrom 12 Years to 17 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Drug study icon
CompletedNCT03247543

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD

This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication SPN-812 in practice and what may need to be adjusted.

Multiple locations, including Long Beach
ADHDDrugFrom 6 Years to 11 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Drug study icon
CompletedNCT04016779

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD

This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand whether the medication SPN-812 can improve attention, thinking, or day-to-day functioning.

Multiple locations, including Garden Grove
ADHDDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Drug study icon
CompletedNCT03247517

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD

This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication SPN-812 in practice and what may need to be adjusted.

Multiple locations, including Dothan
ADHDDrugFrom 12 Years to 17 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Drug study icon
CompletedNCT03247530

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD

This study exists to understand whether the medication SPN-812 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication SPN-812 in practice and what may need to be adjusted.

Multiple locations, including Dothan
ADHDDrugFrom 6 Years to 11 Years
Countries
United States
Sponsor
Supernus Pharmaceuticals, Inc.
Condition
ADHD
Behavioral study icon
Enrolling By InvitationNCT03970005

Evaluation of Step-Based Care for Individuals at Clinical High Risk for Psychosis

This study is looking at evaluate the long-term outcomes among individuals participating in this clinical service for people with Prodromal Schizophrenia. Participants are followed over time so researchers can learn from clinical and follow-up information.

In Columbus
SchizophreniaBehavioralFrom 12 Years to 25 Years
Countries
United States
Sponsor
Ohio State University
Condition
Schizophrenia
Drug study icon
CompletedNCT00050804

Evaluation of Stress Disorders

This summary needs review. Please check the official study record and contact the research team for details.

In Bethesda
PTSDDrug
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
PTSD
Other study type icon
TerminatedNCT01663974

Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolarity

This study exists to understand how this type of care holds up over time after the earliest research stage. Researchers are trying to understand what this type of care could change in day-to-day care and decision-making.

Multiple locations, including Aix-en-Provence
Bipolarity, DepressionOtherOver 18 Years
Countries
France
Sponsor
AstraZeneca
Condition
Bipolarity, Depression
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.